Study | Sample No. | Method | Expression | Correlation with Grade or Stage | Correlation with Survival |
---|---|---|---|---|---|
Breast cancer | Â | Â | Â | Â | Â |
Kang et al., 2003 (41) | 320 | IHC | 229 (72%) samples low expressing 91 (28%) samples high expressing | N/A | High matriptase expression predictive of poor survival |
Parr et al., 2004 (40) | 120 | qRT-PCR | Matriptase was not significantly increased in tumors compared with normal breast tissue | No correlation | No correlation |
Cervical cancer | Â | Â | Â | Â | Â |
Santin et al., 2003 (39) | 19 | IHC/RT-PCR | 0/8 (0%) in normal squamous epithelia 6/6 (100%) in SCC 2/5 (40%) in adenocarcinomas | N/A | N/A |
Lee et al., 2005 (25) | 89 | IHC/LCM/RT-PCR | 0/10 (0%) in normal squamous epithelia 4/19 (21%) in LSIL 12/20 (60%) in HSIL 38/40 (95%) in invasive SSC | Frequency of matriptase detection increased with histopathological grade | N/A |
Ovarian cancer | Â | Â | Â | Â | Â |
Tanimoto et al., 2005 (38) | 96 | IHC/sqRT-PCR | 0/7 (0%) of normal ovarian tissue 50/89 (56%) of ovarian carcinomas | Matriptase more frequently expressed in stage 1 tumors compared with advanced stage tumors | Positive correlation between matriptase expression and overall survival |
Oberst et al., 2002 (43) | 54 | IHC | 39/54 (72%) of ovarian carcinomas expressed matriptase | Matriptase more frequently expressed in stage 1 tumors compared with advanced stage tumors | N/A |
Prostate cancer | Â | Â | Â | Â | Â |
Riddick et al., 2005 (35) | 67 | qRT-PCR | Significant increase (2–3 fold) of matriptase expression in malignant vs. nonmalignant samples | Significant positive correlation with Gleason score | N/A |
Gastrointestinal cancer | Â | Â | Â | Â | Â |
Zeng et al., 2005 (36) | 77 | qRT-PCR | Significant downregulation of matriptase in gastric and colorectal cancer compared with adjacent normal tissue | No significant correlation with stage or lymph node metastasis status | N/A |